An experimental brain tumor vaccine showed encouraging long-term survival results in a small early-stage trial.
“Although this evidence came from only one participant, it suggests that the vaccine could generate a targeted immune response within the brain. Because this was a small, early-stage trial with no comparison group, it cannot prove that the vaccine is safe or that it improved survival.”